Eupraxia Reports Strong Positive Phase 1b/2a Data for EoE Drug EP-104GI, Showing Near-Complete Tissue Health Improvement
EPRX has more than doubled off its 52-week low of $2.68 on elevated volume (2.7× avg).
Summary
Eupraxia Pharmaceuticals reported positive Phase 1b/2a clinical trial data for its EoE drug EP-104GI, showing near-complete tissue health improvement and sustained clinical remission with a favorable safety profile.
Key Events · Product Development and Regulatory · EPRX
-
Positive Tissue Health Data
The highest dose of EP-104GI achieved near-complete normalization of tissue health at 12 weeks in the RESOLVE trial for Eosinophilic Esophagitis (EoE), with lower doses maintaining improvements for up to 36 weeks.
-
Sustained Clinical Remission
Clinical remission was achieved by 8 weeks and maintained through 52 weeks in a majority of patients who had at least 60% of their esophagus treated with EP-104GI.
-
Favorable Safety Profile
Over 200 patient-months of follow-up reported no Serious Adverse Events (SAEs) or cases of oral candidiasis, indicating EP-104GI was well tolerated at all dose levels.
-
Advancing to Phase 2b
The Phase 2b part of the RESOLVE trial is actively recruiting, with top-line data anticipated in Q3 2026.
Analysis · EPRX · Life Sciences
Eupraxia Pharmaceuticals announced highly positive 12-week and 36-week tissue health data from its RESOLVE trial for EP-104GI in eosinophilic esophagitis (EoE). The highest dose achieved near-complete normalization of tissue health, with lower doses maintaining improvements for up to 36 weeks. The drug also demonstrated clinical remission maintained through 52 weeks in a majority of patients and a strong safety profile with no serious adverse events. This data significantly de-risks the EP-104GI program and provides strong validation for its potential as a once-yearly treatment for EoE, a condition with high unmet medical need. The positive results reinforce the stock's current position near its 52-week high. Investors should monitor the progress of the ongoing Phase 2b trial, with top-line data expected in Q3 2026.
At the time of this filing, EPRX was trading at $7.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $395.8M. The 52-week trading range was $2.68 to $8.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.